PUBLISHER: Grand View Research | PRODUCT CODE: 1405818
PUBLISHER: Grand View Research | PRODUCT CODE: 1405818
The India large volume parenteral market size is expected to reach USD 134.0 million by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 6.0% from 2021 to 2028. Large Volume Parenteral (LVP) injections are used for either total or partial nutrition when oral intake is insufficient or challenging. Earlier, these formulations were used for patients undergoing surgical procedures or those admitted to a hospital.
Currently, they are used as substitutes for nutrition obtained from a healthy diet. However, the demand for LVPs has significantly increased due to the growing adoption of parenteral nutrition over enteral nutrition among COVID-19 patients for improving drug absorption, shorter hospital stays, and reduced risk of infections. This is anticipated to drive the market over the forecast period.
In 2020, the nutritious injections application segment accounted for the largest revenue share. This is attributed to the growing adoption of these products in delivering intravenous carbohydrates, amino acids, electrolytes, and minerals to meet adequate nutritional requirements when enteral nutrition mode is insufficient, not possible, or contraindicated. On the other hand, the therapeutic injections segment is anticipated to register the fastest growth during the forecast period. The increasing prevalence of chronic conditions, such as cancer, can significantly impact the adoption of LVPs in the country, as they can provide vital nutrients to help maintain strength, energy, and hydration in patients from diagnosis to recovery.
In 2020, the 500 ml volume segment accounted for the largest revenue share. The increasing number of ICU admissions, rising demand for parenteral formulation among critically ill patients, growing preference for single-dose administration of vaccines and drugs, and increasing prevalence of various chronic disorders such as cancer and diabetes are some of the factors expected to propel this segment. On the other hand, the 100 ml volume segment is anticipated to register the fastest growth during the forecast period, as it can help avoid adverse effects related to nutrition and electrolyte imbalances.
In 2020, the hospital and other healthcare facilities segment dominated the market. The segment is anticipated to maintain its dominance during the forecast period. The growing prevalence of chronic conditions requiring dietary management in patients and increasing incidence of hospital-acquired malnutrition are expected to boost demand for LVPs. In addition, these formulations are administered preoperatively to reduce the rate of complications and hospital stay among surgical ICU patients. This is likely to increase the demand for LVPs among surgical and intensive care patients, thereby, propelling segment growth.